Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose–response meta-analysis.

Purpose: Aspirin has been suggested to reduce the risk of cancer. However, previous studies have been inconsistent regarding the relationship between aspirin use and the risk of occurrence of hepatocellular carcinoma (HCC). The purpose of this study was to assess the effect of aspirin on clinical ou...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Clinical Pharmacology Vol. 79; no. 1; pp. 39 - 62
Autores principales: Ma, Shaodi, Qu, Guangbo, Sun, Chenyu, Liu, Haixia, Jiang, Yuemeng, Li, Ning, Wu, Birong, Gao, Juan, Feng, Linya, Xie, Peng, Xia, Weihang, Kim, Na Hyun, Lowe, Scott, Bentley, Rachel, Zhu, Yike, Zhou, Qin, Sun, Yehuan
Formato: meta analysis research systematic review tables/charts Journal Article
Publicado: Springer Nature Jan2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=161159751&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 161159751
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00316970
        NP9
      jtl: European Journal of Clinical Pharmacology
      issn: 00316970
      maglogo: N
    pubinfo:
      dt: Jan2023
      vid: 79
      iid: 1
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        161159751
        160026621
        161159751
        161159751
        10.1007/s00228-022-03414-y
        161159751
      ppf: 39
      ppct: 23
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose–response meta-analysis.
      aug:
        au:
          Ma, Shaodi
          Qu, Guangbo
          Sun, Chenyu
          Liu, Haixia
          Jiang, Yuemeng
          Li, Ning
          Wu, Birong
          Gao, Juan
          Feng, Linya
          Xie, Peng
          Xia, Weihang
          Kim, Na Hyun
          Lowe, Scott
          Bentley, Rachel
          Zhu, Yike
          Zhou, Qin
          Sun, Yehuan
        affil: Department of Epidemiology and Health Statistics, School of Public, Health Anhui Medical University, No. 81 Meishan Road, 230032, Hefei, Anhui, People's Republic of China
      sug:
        subj:
          Carcinoma, Hepatocellular Drug Therapy
          Carcinoma, Hepatocellular Mortality
          Carcinoma, Hepatocellular Prevention and Control
          Incidence
          Recurrence
          Aspirin Therapeutic Use
          Treatment Outcomes
          Dose-Response Relationship
          Human
          Systematic Review
          Meta Analysis
          Confidence Intervals
          Descriptive Statistics
      ab: Purpose: Aspirin has been suggested to reduce the risk of cancer. However, previous studies have been inconsistent regarding the relationship between aspirin use and the risk of occurrence of hepatocellular carcinoma (HCC). The purpose of this study was to assess the effect of aspirin on clinical outcomes in patients with HCC in a meta-analysis and to explore the possible dose–response relationship. Methods: A systematic literature search was conducted in 10 electronic databases and 4 registries. The combined hazard ratios (HRs) were calculated using a random-effects model with 95% confidence interval (CIs) to assess the effect of aspirin on the risk of HCC. Relevant subgroup analyses and sensitivity analyses were performed. Results: The results show that aspirin use correlated with lower incidence of HCC (HR: 0.75, 95% CI: 0.71–0.80), decreased risk of HCC recurrence (HR: 0.79, 95% CI: 0.65–0.96), and reduced mortality (HR: 0.72, 95% CI: 0.60–0.87). The results of the subgroup analysis showed that aspirin use was consistently associated with reduced incidence of HCC across different regions, study designs, and populations. A linear relationship was found for both dosage and duration of aspirin use. An increased of bleeding with aspirin use among patients was also observed (HR 1.10, 95% CI: 1.02–1.20). Conclusions: This meta-analysis found that aspirin use was independently associated with a reduced risk of HCC incidence, recurrence, and death. Furthermore, aspirin use influenced HCC occurrence in a dose-dependent and duration-dependent manner. However, an increased risk of bleeding with aspirin use was noted.
      pubtype: Academic Journal
      doctype:
        meta analysis
        research
        systematic review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N